Companies · SNY
Sanofi
AI-generated · informational only · not investment advice · verify before relying.
Latest analysis
Updated Oct 30, 2026
Sanofi posts EUR 14.4B Q3 2026 sales (+14.3%), upgrades FY guidance to low-teens sales growth, and restructures Regeneron alliance to secure four next-generation IL-13/IL-4 assets as Dupixent LOE hedge.
Dupixent surpassed EUR 5 billion for the second consecutive quarter, reaching EUR 5.7 billion in Q3 2026, with growth driven by demand and favorable gross-to-net adjustments — approximately 85-90% of which management characterizes as recurring. Sanofi upgraded FY2026 guidance to low-teens sales growth (13-15%) and mid-teens business EPS growth (15-17%), while the expanded Regeneron alliance — adding four long-acting monoclonal antibodies targeting type 2 inflammation — marks the first concrete step in building a post-LOE pipeline. Pipeline discontinuations of amlitelimab (AD) and itepekimab (COPD/CRS), combined with a strategic commitment to immunology, rare diseases, and vaccines as the only capital-allocation focus areas, signal a sharp portfolio reset under new R&D head Paolo Fontoura.
Tone: bullishRevenue
€43.6B
SNY 20-F · FY 2025 · EUR
Revenue FY2024
€41.1B
Founded
1994
Headquarters
Paris, France
Profile
SNY 20-F Item 4.B · Feb 17, 2026Sanofi is a French R&D-driven, AI-powered biopharma company that discovers, develops, and commercializes medicines and vaccines across immunology, rare diseases, neurology, oncology, and vaccines. Its lead product, Dupixent (dupilumab), is a blockbuster biologic targeting type 2 inflammation approved across multiple indications globally. The company operates a single Biopharma segment following the April 2025 divestiture of a controlling stake in its consumer healthcare business, Opella, to Clayton, Dubilier & Rice.
Read filing description ↓ Collapse description ↑
Sanofi is an R&D driven, AI-powered biopharma company committed to improving people's lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people's lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. The Biopharma operating segment comprises commercial operations and research, development and production activities relating to the Specialty Care, General Medicines, and Vaccines franchises plus support and corporate functions, for all geographical territories. Sanofi's activities are organized around the following categories within the Biopharma operating segment: Immunology, Rare Diseases, Neurology, Oncology, Other Medicines and Vaccines. We have business operations in approximately 60 countries and our products are available in more than 160 countries. Sanofi is the ninth largest pharmaceutical company globally by sales. We are on a mission to go further, faster for patients. We seek to take the lead through breakthrough science and by leveraging our broad set of technology and manufacturing platforms, including mRNA. To transform the practice of medicine, we are developing and deploying AI-powered solutions across all business units at all levels of Sanofi, not only to increase automation and efficiency, but also to fundamentally change the way we work and think.
Primary products
- Dupixent (dupilumab)
- Kevzara (sarilumab)
- Cerezyme (imiglucerase)
- Cerdelga (eliglustat)
- Myozyme/Lumizyme (alglucosidase alfa)
- Nexviazyme/Nexviadyme (avalglucosidase alfa-ngpt)
Business segments
End markets
Geographies
Named competitors
“Sanofi is the ninth largest pharmaceutical company globally by sales.” Competitive position, as stated in the filing
Revenue commentary · FY 2025
Reported in EUR. Net sales rose 6.2% on a reported basis in 2025; at constant exchange rates (CER), net sales rose 9.9%, driven mainly by strong performances for Dupixent and increased sales of ALTUVIIIO.
The rest of SNY is for subscribers
Analysis, signals, diligence answers, M&A activity and every quote, each citing the filing it came from.